Metelimumab

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]

Metelimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTGF beta 1
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

History

Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]

In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]

Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]

gollark: It does nothing whatsoever.
gollark: Mildly weird question, how come `wall` doesn't work over SSH on my void system?
gollark: ddnscrypt-proxy is also go.
gollark: I mean, yggdrasil is go.
gollark: Ah yes, fair.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.